GLPG – galapagos nv - american depositary shares (US:NASDAQ)
Stock Stats
News
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma [Yahoo! Finance]
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Galapagos NV (NASDAQ: GLPG) was downgraded by analysts at Kepler Capital Markets from a "hold" rating to a "reduce" rating.
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
Galapagos NV (NASDAQ: GLPG) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $30.00. They now have a "sector perform" rating on the stock.
Form 6-K GALAPAGOS NV For: Dec 07
Form S-8 GALAPAGOS NV
Form SC 13G/A GALAPAGOS NV Filed by: FMR LLC
Form 6-K GALAPAGOS NV For: Nov 05
Form 6-K GALAPAGOS NV For: Oct 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.